Three-in-one incidence of hepatocellular carcinoma, cholangiocellular carcinoma, and neuroendocrine carcinoma: A case report

Table 2 Partial clinical data of patients

Gender	Age (yr)	Country	Site of primary lesion	Hepatitis	AFP (μg/L)	Ki-67	Therapy	Lifetime
Male	61	China	Liver	B	1210	5%	Surgical resection + TACE	Short
Male	54	China	Liver	B	1400	80%	Surgical resection + TACE	2 mo
Male	19	United States	Liver	/	Normal	High	Surgical resection + Cisplatin and gemcitabine chemotherapy	> 8 mo
Female	65	United States	Rectum	C	2198	High	Surgical resection + Cisplatin and gemcitabine chemotherapy	5 mo
Male	32	United States	Liver	B	4519	60%	Surgical resection + TACE	4 mo

AFP: Alpha-fetoprotein; TACE: Transarterial chemoembolization.